PCN1 Use of the 5-HT3-RA Antiemetics in the Prevention and Treatment of Radiation Induced Nausea and Vomiting  by Knoth, R.L. et al.
clinical rational for lumbar fusion surgery. Patients who underwent a ALIF, PLF or
T/PLIF with stand-alone DDD had significantly lower total payments and signifi-
cantly shorter LOS, while patients with DDD and additional back diagnoses had
significantly higher total payments and longer LOS compared to patients who un-
derwent an ALIF, PLF, or T/PLIF without a comorbid diagnosis of DDD.
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OBJECTIVES: Compare resource utilization and medical charges among patients
who had an anterior lumbar interbody fusion (ALIF), posterior lumbar interbody
fusion (PLF), or transforaminal posterior lumbar interbody fusion (T-PLIF) and a
subsequent revision surgery to those without such a revision surgery. METHODS:
The MedStat MarketScan databases from 2006 - 2009 were utilized for this retro-
spective analysis. Patients were included if had a ALIF, PLF, or T-PLIF and had
continuous insurance coverage for 2 years post procedure. Revision patients were
then matched to non-revision patients at a 2:1 ratio based upon type of initial
procedure, year of birth, sex, and region of residence Medical payments and re-
source utilization were compared between the two cohorts using t-statistics for
continuous variable and chi-square statistics for categorical variables. RESULTS: In
the 2 years post procedure, patients with a subsequent revision were significantly
more likely to visit a physical therapist (92% v 62%; P0.0001), receive an epidural
steroid injection (58% v 47%; P0.0074), or visit the emergency room with a diag-
nosis of back pain (20% v 9%; P0.0001). The average cost the initial surgery was
similar among the two cohorts ($39,925 v $38,341; P0.6422) while the mean cost
associated with a revision surgery was $35,296 (std dev$32,814). Total payments
for the two cohorts, ignoring the cost of the initial procedure was $33,180 for pa-
tients who did not have a subsequent revision, and $89,770 for patients with a
subsequent revision (P0.0001). These differences translate into a $56,590 cost
premium associated with a revision surgery – 62% of which can be accounted by the
revision surgery itself. CONCLUSIONS: Revision surgery was associated with sig-
nificantly more resource utilization post initial surgery. Comparing costs among
the two groups reveal a significant cost premium associated with revision surgery
and that such costs extended beyond the cost of the revision surgery itself.
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OBJECTIVES: Tuberous sclerosis complex (TSC) is a rare genetic disorder charac-
terized by benign tumor growth in multiple organs. TSC’s subsequent and varied
impacts on patients are typically treated by many different types of procedures.
This study aimed to assess the principal clinical manifestations imposed by the
disease and consequent major types of health care resource utilization experi-
enced among TSC patients in the United States (US). METHODS: An Institutional
Review Board-approved Internet-based survey of US TSC patients and caregivers
solicited information on prevalence of manifestations, disease management, and
impact on patients. Descriptive statistics were calculated. RESULTS: Of the 380
initial respondents, 53% were patients and 47% were caregivers. Surveys provided
data on 380 patients, of whom 59% were female and the mean age was 30.4 years
(SD: 17.3; median: 32.5). The majority of patients reported experiencing skin lesions
(53%) while seizures, cognitive concerns, cerebral tumors, angiomyolipomas (AML),
and subependymal giant cell astrocytomas (SEGA) were reported by 46%, 36%, 26%,
23%, and 21%, respectively. Ninety patients (24%) reported only one manifestation
of TSC, while 18%, 14%, and 38% reported 2, 3, or 4 or more. Over half of patients
(52%) had some type of TSC-related surgery including but not limited to brain
surgery (33%), embolization (12%), nephrectomy (7%), kidney transplant (6%), and
laser surgery (12%). Patients with SEGAs reported the highest level of brain surgery
(55%). Among patients with AMLs, embolization for kidney lesions (28%), nephrec-
tomy (12%) and kidney transplant (8%) were reported. CONCLUSIONS: In this anal-
ysis of initial respondents, TSC presents significant, and varied, epidemiological
and clinical burden in the US. Patients with SEGA and AMLs seemed to experience
the highest rates of invasive procedures among all patients with TSC.
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OBJECTIVES: The number of performed heart transplantations per year are well
published and can easily be accessed. Nevertheless, there are no exact figures on
the prevalence and incidence of patient survival after heart transplantation in
Germany, although these patients have high health care needs. Purpose of this
study was to generate these missing figures for the past and present as well as
taking an outlook into the future development until 2030. METHODS: Primarily
based on statistics from the Federal Statistical Office and liver transplant quality
reports of the German AQUA-Institute, relevant parameters and data were identi-
fied and used to develop an epidemiological model. Key drivers of the model are
yearly patient survival rates as well as growth rates of performed liver transplan-
tations. The model starts in 1987 and is able to predict the future development of
the cumulative liver transplant patient population until the year 2030. To account
for uncertainty, a 1.000 replication Monte-Carlo-Simulation with random samples
within published ranges of the input parameters was run. RESULTS: According to
our model currently (2012) about 7.773 (95% Confidence interval: 7.701 – 7.844)
patients with prior liver transplantation live in Germany. Until 2030 the model
estimates an increase of the population size to 17.490 (95% CI: 17.105 – 17.875)
people. The number of performed liver transplantations is estimated at 3.068 (95%
CI: 2.988 – 3.148) in 2030. CONCLUSIONS:With current assumptions the liver trans-
plant patient population size will continuously grow. The growth of this population
will primarily be limited by available organs for transplantation.
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OBJECTIVES: The number of performed heart transplantations per year are well pub-
lished and can easily be accessed. Nevertheless, there are no exact figures on the preva-
lence and incidence of patient survival after heart transplantation in Germany, although
these patients have high health care needs. Purpose of this study was to generate these
missing figures for the past and present as well as taking an outlook into the future de-
velopment until 2030.METHODS: Primarily based on statistics from the Federal Sta-
tistical Office and heart transplant quality reports of the German AQUA-Institute
relevant parameters and data were identified and used to develop an epidemiolog-
ical model. Key drivers of the model are yearly patient survival rates as well as
growth rates of performed heart transplantations. The model starts in 1980 and is
able to predict the future development of the cumulative heart transplant patient
population until the year 2030. To account for uncertainty, a 1.000 replication Mon-
te-Carlo-Simulation with random samples within published ranges of the input
parameters was run. RESULTS:According to our model currently (2012) about 4.072
(95% Confidence interval: 4.028 – 4.116) patients with prior heart transplantation
live in Germany. Until 2030 the model estimates a decrease of the population to
3.028 (95% CI: 2.980 – 3.077) people. Peak number of patients after heart transplan-
tation was estimated at 2007: 4.225 (95% CI: 4.192 – 4.257). The number of performed
heart transplantations is estimated at 266 (95% CI: 261-271) in 2030.CONCLUSIONS:
Even though the peak number of patients with heart transplants according to our
model has occurred in the past, still a considerable heart transplant patient popu-
lation is living at Germany and seeking health care services for their needs.
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INTRODUCTION: Evidence based medicine (EBM) is frequently used as the basis for
clinical guidelines and reimbursement recommendations. The hierarchy of evi-
dence is: Level I - randomized controlled trials (RCTs); Level II - nonrandomized
cohort studies; Level III - case control studies, Level IV - case series, and Level V -
expert opinion. RCTs are generally required when developing clinical guidelines or
reimbursement recommendations for drugs.OBJECTIVES:The purpose of this case
review is to illustrate an application of EBM to an innovative surgical procedure and
highlight how the recommendations for use changed with new evidence.
METHODS: NICE guidelines for arthroscopic surgery for femoro-acetabular im-
pingement were reviewed. This case study was selected because the treatment
modality represents a new surgical technology in which guidelines for coverage
recommendations, first promulgated in 2007, were later changed in 2011, illustrat-
ing the impact of additional evidence generation. RESULTS: In 2007, efficacy evi-
dence considered by NICE were two case series, with 158 and 10 patients respec-
tively. In 2011, efficacy evidence considered by NICE covered 1126 patients from 3
non-randomized controlled studies (none compared with natural history or non-
arthroscopic surgical techniques), 5 case series (with 100 to 200 hips), and 1 case
report. Twenty-two smaller case series were also identified. In 2011, four out of five
specialist advisors viewed the procedure as established while one advisor consid-
ered the efficacy and safety still to be uncertain. In 2007, NICE concluded “current
evidence . . . does not appear adequate for this procedure to be used without special
arrangements for consent and for audit or research” while in 2011 NICE concluded
“current evidence. . ... is adequate in terms of symptom relief in the short and
medium term.” CONCLUSIONS: For innovative surgical procedures in the UK, non-
randomized controlled studies and case series, supported by specialist recommen-
dation, may be sufficient for a positive recommendation by NICE.
DISEASE-SPECIFIC STUDIES
CANCER - Clinical Outcomes Studies
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OBJECTIVES: Radiation-induced nausea and vomiting (RINV) is commonly experi-
enced by cancer patients undergoing radiation treatment. Current NCCN guide-
lines recommend the use of the 5-hydroxytryptamine-3 serotonin receptor antag-
onists (5-HT3-RAs) for the prevention and treatment of RINV. The purpose of this
study was to examine the incidence of 5-HT3-RA utilization and subsequent RINV,
in patients diagnosed with colon cancer and undergoing radiation treatment.
METHODS: This was a retrospective analysis using HIPAA-compliant medical and
pharmacy claims in a commercially-insured U.S. patient population. The study
identified continuously enrolled adult patients diagnosed with colon cancer who
received radiation treatment during the period from 4/1/2007 to 8/31/2009. Patients
receiving combination chemotherapy were excluded. The index date was the date
of initiation of radiation treatment and patients were followed for 30 days. Prophy-
lactic administration of a 5-HT3-RA was defined by medication on the day of or the
day prior to radiation therapy. The incidence of RINV was calculated from medical
claims for an outpatient appointment, inpatient admission, or ER visit with a pri-
mary diagnosis of RINV. RESULTS: A total of 2,400 patients were identified as
meeting the inclusion and exclusion criteria for the study. Average age of patients
was 57.6 years old and 43.8% were female. Radiation therapy included localized
treatment (48.6%), total body irradiation (30.9%), or both (20.5%). Of the patients
identified, 73.9% received no 5-HT3-RA, 5.0% were treated prophylactically, and
21.1% received a 5-HT3-RA in the days after radiation therapy. Of the patients who
received the 5-HT3-RA prophylactically, 58.2% were treated with an oral formula-
tion. Incidence of subsequent RINV for all patients, independent of rescue medica-
tion use, was 15.2%. CONCLUSIONS: The results showed use of the 5-HT3-RA an-
tiemetics in patients undergoing radiation treatment for colon cancer was
uncommon and prophylactic administration was relatively rare.
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OBJECTIVES: To determine the number of patients with diagnosed acute myeloid
leukaemia (AML) including chemotherapy rates, types and care settings using sick-
fund data. METHODS: Data provided by 4 statutory sick funds (SHI) and 2 data
providers were analyzed for 2010. AML diagnosis was identified by ICD-10 C92.0
and other types of cancer by ICD-10 C00-79; D00-09; D37-48. Prevalence was extrap-
olated to the German population by correcting for a representative age- and gender
distribution. RESULTS: The median proportion of AML patients  60 years was
61.1% or 6,590 patients (SHI A: 63.0% 4,938; B: 50.9% 5,858; C: 68.9% 8,975). The
proportion of AML patients  65 years (sick fund D) was 47.6% or 4,400 patients.
Gender ratio was 57% male and 43% female. On average, 2 additional oncological
disorders were found in 77% of AML patients. 50% had an unspecified leukaemia
(C95.90), 25% had CML (C92.1*) and 20% MDS (D46.9). Among patients65 years the
rate of treatment was 60.9% (Anatomical Therapeutic Chemical (ATC) Code L01*
(40%), pharmacy number (PZN) 9999092 (19%), operating and procedure code (OPS)
854* (26%)). 16.4% received both out- and inpatient treatment, 34.5% received out-
patient treatment and 10.0% inpatient treatment. Identification of comppunds was
possible when ATC codes were reported. 63.6% received imatinib and/or hydroxy-
carbamide, 11.4% tioguanine, 9.1% mercaptopurine, 9.1% cytarabine and 6.8% re-
ceived dasatinib. The outpatient treatment rate in patients  60 years diagnosed
with AML only was 34.3% (6,2% mercaptopurine and idarubicine, 28.1% PZN
9999092). CONCLUSIONS: Prevalence was higher than previously reported inci-
dence numbers of 3,100 AML patients (SHI, all age groups). The yearly outpatient
treatment rate was relatively low with 34.3% in patients diagnosed with AML alone.
Other oncological disorders are likely to be diagnosed before AML diagnosis could
be confirmed. Treatment rates increased with additional oncological disorders
with the use of substances not approved for AML.
PCN3
QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH WILD-TYPE (WT) KRAS
METASTATIC COLORECTAL CANCER (MCRC) RECEIVING FIRST-LINE THERAPY
WITH PANITUMUMAB PLUS FOLFOX VERSUS FOLFOX ALONE
Wang J1, Zhao Z2, Barber B2, Zhang J1, Sherrill B1, Braun S3, Sidhu R2, Gallagher M2,
Douillard JY4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Amgen Inc., Thousand Oaks, CA, USA,
3Amgen (Europe) GmbH, Zug, Switzerland, 4ICO R. Gauducheau, ST HERBLAIN, France
OBJECTIVES: Panitumumab plus FOLFOX significantly improved progression-free
survival (PFS) in patients with WT KRAS mCRC. The objective of this analysis was to
use the quality-adjusted time without symptoms of disease or toxicity of treatment
(Q-TWiST) method to compare quality-adjusted survival between the treatment
arms. METHODS: Patients with mCRC were randomized to panitumumab plus
FOLFOX or FOLFOX alone in a phase III clinical trial. For each treatment arm, the
area under the survival curve, which was estimated using the Weibull distribution,
was partitioned into health states: toxicity (TOX), time without symptoms of dis-
ease progression or toxicity (TWiST, i.e., PFS minus TOX), and relapse period (REL,
i.e., overall survival (OS) minus PFS); and adjusted using utility weights derived
from patient-reported EuroQoL 5-dimensions measures. The null hypothesis of no
difference between treatment groups was tested based on the normal approxima-
tion with standard errors calculated by the bootstrap method. Sensitivity analyses
were performed using the standard Q-TWiST approach with means restricted to
median OS. RESULTS: Of 1,183 patients who were randomly assigned, 1,096 pa-
tients (93%) had available tumor KRAS status, of which 656 patients (60%) had WT
KRAS tumors (panitumumab plus FOLFOX, n325; FOLFOX alone, n331) and were
included in this analysis. Compared to patients treated with FOLFOX alone, the
panitumumab plus FOLFOX group had significantly longer quality-adjusted PFS
(8.5 versus 7.2 months, respectively; 1.3 additional quality-adjusted months; p 
0.02) and quality-adjusted OS (22.4 versus 18.6 months; 3.8 additional quality-ad-
justed months; p 0.04). When analysis was restricted to 24 months follow-up, the
Q-TWiST advantage was smaller but still significant (14.0 versus 13.0 months; 1.0
additional quality-adjusted month; p  0.04). CONCLUSIONS: This Q-TWiST anal-
ysis showed that in patients with previously untreated WT KRAS mCRC, panitu-
mumab plus FOLFOX significantly improved the duration of the quality-adjusted
survival compared with FOLFOX alone.
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OBJECTIVES: About a decade ago, the introduction of the tyrosine kinase inhibitor
(TKI) imatinib dramatically extended the life span of chronic myeloid leukemia
(CML) patients. Currently, there are several different TKIs approved for CML treat-
ment. The goal of this study is to develop a clinical decision-analytic model for the
evaluation of the comparative long-term effectiveness of first-line therapy for CML
within the Austrian health care context.METHODS:We developed a Markov state-
transition model for patients in the chronic-phase of CML treated with first-line TKI
imatinib, dasatinib or nilotinib. Seven different strategies including different com-
binations of first and second-generation TKIs as well as chemotherapy or stem cell
transplantation were evaluated. The model was parameterized using published
trial data, data from the Austrian CML registry and from an Austrian CML expert
panel. The model was analyzed as a cohort simulation over a lifelong time horizon.
Health outcomes evaluated were life-years (LYs) gained and quality-adjusted life
years (QALYs) gained. Deterministic and structural sensitivity analyses were
performed. RESULTS: Nilotinib followed by dasatinib after failure is the most ef-
fective treatment in terms of both LYs gained (19.71 LY) and QALYs gained (17.08
QALYs). All strategies including a second-line TKI were superior compared to strat-
egies without second-line TKI. Deterministic sensitivity analyses showed that the
ranking of the strategies was mostly influenced by the duration of first- and sec-
ond-line therapies. In a structural sensitivity analysis, where patients move di-
rectly from second-line TKI therapy to advanced stage of disease, strategies with-
out second-line therapy are most effective. CONCLUSIONS: Based on our analyses
results, the most clinically effective strategy is nilotinib followed by dasatinib as
second-line therapy. All three TKIs are approved as first-line therapy in Austria.
Our results may support clinicians and patients in their decision making.
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OBJECTIVES: A combination Cabazitaxel plus Corticosteroids (CC) has been shown
to prolong survival in patients with mHRPC versus Mitoxantrone plus Corticoste-
roids (MC) in the TROPIC study of patients with mHRPC. As there is no direct
comparison CC vs. Corticosteroids (C) as requested by the German regulatory bod-
ies we aimed to provide an indirect comparison.METHODS:A systematic search of
the DIMDI database was conducted in 12/2011. Data were combined using meta-
analyses and indirect comparisons (“Bucher et al. J Clin Oncol 2008”). The end-
points analysed were all cause mortality overall and in patients with or without
pain and pain response (Hazard/Response Ratios with 95%-confidence intervals).
RESULTS: A total of 168 potential publications resulted in three relevant studies
(Berry, 2002; Kantoff, 1999; Tannock, 1996) for MC vs. C. A meta-analysis of mortal-
ity in the three studies resulted in HR0.92 (95%-CI 0.74-1.13) for MC vs. C. Com-
bined with TROPIC (CC vs. MC 0.70; 0.59-0.83) the indirect comparison (CC vs. C)
resulted in HR0.64 (0.49-0.84). For mortality in patients without pain at baseline,
the HR for MC vs. C was 0.89 (0.59-1.34) (Berry). The indirect comparison CC vs. C
resulted in HR0.51 (0.30-0.84) using TROPIC patients without pain (HR0.57; 0.42-
0.77). For mortality in patients with pain at baseline, the HR for MC vs. C was 0.83
(0.60-1.16) (Tannock). The indirect comparison CC vs. C resulted in HR0.65 (0.43-
0.98) using TROPIC patients with pain (HR0.78; 0.60-1.00). In patients with pain at
baseline, pain response was higher with MC vs. C (RR2.33; 1.19-4.57) (Tannock).
The indirect comparison CC vs. C resulted in RR2.77 (1.05-7.32) using TROPIC
patients with pain (RR1.19; 0.59-2.39). CONCLUSIONS: The analyses indicate a
statistically significant reduction of mortality in patients with mHRPC receiving CC
vs. C with or without pain and an increased pain response.
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